Table 1.
Summary of patient characteristics.
| Patient characteristics | Overall (n = 1874) |
|---|---|
| Age (year), median (IQR) | 62 (51-71) |
| NPI, median | 4 |
| Menopause | 78.3% |
| ER positive status | 76.6% |
| PR positive status | 53.0% |
| HER2-positive status | 12.4% |
| Three genes status, mode (%)a | 3 (32.3%) |
| Claudin subtypes, mode (%)b | 3 (35.7%) |
| Chemotherapy | 20.8% |
| Hormonal therapy | 61.7% |
| Radiotherapy | 60.3% |
| Surgery, mode (%) | 1 (59.1%) |
| Tumor size (mm), median (IQR) | 51.0 (30.3-63.0) |
| Tumor grade, median | 2 |
| Tumor stage, median | 3 |
| Laterality, mode (%) | −1 (49.3%) |
| Cellularity, median | 2 |
| Oncotree code, mode (%)c | 4 (79.1%) |
| Outcomes | |
| 5-year survival | 75.2% |
| 10-year survival | 47.7% |
| 15-year survival | 26.4% |
Table includes all clinicopathological features used in machine learning models.
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor; IQR, interquartile range; METABRIC, Molecular Taxonomy of Breast Cancer International Consortium; NPI, Nottingham Prognostic Index; PR, progesterone receptor.
a
Three genes status: ER, HER2, and Aurora kinase A (AURKA) activity.
b
Claudin (PAM50) subtypes: luminal A, luminal B, HER2-enriched, basal-like, and Claudin-low.
c
Oncotree code: tumor types based on Oncotree reported in METABRIC dataset.